Market Performance - The A-share market experienced a collective decline, with the Shanghai Composite Index dropping by 1.02% [1] - The Kexin 100 ETF (588800.SH) fell by 2.85%, while other major indices such as the SSE 50, Kexin 50, ChiNext 50, and Northbound 50 also reported declines [1] ETF and Trading Data - The Kexin 100 ETF (588800) had a latest price of 1.500, with a trading volume of 1.79 billion and a net inflow of 0.39 billion over the last five trading days [2][3] - The ETF's total scale reached 30.58 billion, with an average daily trading volume of 2.53 billion over the past week, indicating good liquidity [3] Sector Performance - In the Kexin 100 Index, major sectors such as semiconductors, batteries, chemical pharmaceuticals, communication equipment, and IT services saw declines of 4.02%, 0.07%, 1.26%, 1.76%, and 1.18% respectively [3] - Among the top 50 weighted stocks in the Kexin 100 Index, notable gainers included Huaxi Biological (up 7.07%), Jinpan Technology (up 6.03%), and Aotwei (up 5.84%), while Ju Chen Co. and Yuntian Lifu faced significant declines of -12.31% and -10.63% respectively [2] Financial Support for Tech Enterprises - The loan support for technology-based SMEs remains strong, with 275,000 companies receiving loans by the end of Q4 2025, achieving a loan approval rate of 50.2%, an increase of 2 percentage points from the previous year [3] - The loan balance for domestic and foreign currency technology-based SMEs reached 3.63 trillion, reflecting a year-on-year growth of 19.8%, outpacing the growth rate of other loan categories by 13.6 percentage points [3] Industry Outlook - According to Industrial Securities, global capital expenditure is experiencing high demand, particularly in computing infrastructure, with a rapid acceleration in the demand for computing power [3] - The domestic AI ecosystem is transitioning from laboratory settings to large-scale applications, with progress in implementation speeding up [3]

Group 1 - On January 30, Changshan Pharmaceutical's stock rose by 5.28%, with a trading volume of 1.538 billion yuan [1] - The company had a financing buy amount of 104 million yuan and a financing repayment of 111 million yuan on the same day, resulting in a net financing buy of -7.81 million yuan [1] - As of January 30, the total margin balance for Changshan Pharmaceutical was 2.608 billion yuan, accounting for 5.12% of its circulating market value, which is above the 90th percentile level over the past year [1] Group 2 - As of January 20, the number of shareholders for Changshan Pharmaceutical was 41,400, an increase of 2.88% from the previous period [2] - The average circulating shares per person decreased by 2.79% to 22,148 shares [2] - For the period from January to September 2025, the company reported an operating income of 681 million yuan, a year-on-year decrease of 13.11%, and a net profit attributable to the parent company of -44.82 million yuan, a decrease of 714.77% year-on-year [2] Group 3 - Since its A-share listing, Changshan Pharmaceutical has distributed a total of 181 million yuan in dividends, with 4.5953 million yuan distributed in the last three years [3] - As of September 30, 2025, Hong Kong Central Clearing Limited was the sixth largest circulating shareholder, holding 3.8944 million shares, a decrease of 6.6577 million shares from the previous period [3]

Group 1 - The company has a total of 17 new products and over 30 research reserve varieties, with several global patent expirations scheduled between 2028 and 2033 [1] - Some products, such as Vabigatran, Rosuvastatin, and others, are already in the registration submission process, indicating ongoing development efforts [1] - The company plans to maintain multiple new product launches each year, creating a product lineup consisting of mature products, research (registration) products, and reserve products [1] Group 2 - Currently, there is no relevant layout in the innovative drug sector, indicating a focus on other areas [1] - The company's associate, Boya Biotech, primarily engages in the research and production of high-difficulty specialty formulations, which have high industry entry barriers [1] - Future business synergies are expected between the company and Boya Biotech, enhancing overall operational capabilities [1]

MACD金叉信号形成，这些股涨势不错！ 【A股限售股解禁一览：600.11亿元市值限售股今日解禁】智通财经2月2日电，Wind数据显示，周一 （2月2日），共有15家公司限售股解禁，合计解禁量为30.34亿股，按最新收盘价计算，合计解禁市值 为600.11亿元。从解禁量来看，信达证券、国邦医药、江瀚新材解禁量居前，解禁股数分别为25.51亿 股、2.57亿股、1.22亿股。从解禁市值来看，信达证券、国邦医药、江瀚新材解禁市值居前，解禁市值 分别为448.79亿元、70.6亿元、39.62亿元。从解禁股数占总股本比例来看，信达证券、国邦医药、诺思 格解禁比例居前，解禁比例分别为78.67%、46.01%、40.66%。 转自：智通财经 ...

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.25 [1][4]. Core Insights - The company has announced a significant overseas transaction involving its long-acting peptide drug metabolism AI discovery platform, which includes a USD 1.2 billion upfront payment, up to USD 3.5 billion in development milestones, and up to USD 13.8 billion in potential sales milestones, along with a double-digit percentage royalty on net sales to AstraZeneca [1][2]. - This transaction is the largest among domestic pharmaceutical companies in the year and is comparable to the 2015 upfront payment scale between 3SBio and Pfizer [1]. - The company is expected to benefit from the upfront payment, leading to a high apparent year-on-year growth in net profit for 2026 [1][3]. Summary by Sections Transaction Details - The deal with AstraZeneca includes a USD 1.2 billion upfront payment, a maximum of USD 3.5 billion in development milestones, and a maximum of USD 13.8 billion in potential sales milestones, along with a double-digit percentage royalty on net sales [2]. - The platform includes core assets such as GIPR/GLP-1R (monthly formulations) and three preclinical weight loss pipelines with different mechanisms of action [2]. Platform Mechanism - The company possesses a globally leading liposome platform, and the fluid crystal technology allows for long-term release of active ingredients, enabling monthly or longer dosing [2]. Pipeline Potential - The company’s pipeline includes significant projects such as EGFR ADC, which is expected to enter Phase III clinical trials both domestically and internationally, and other oncology and autoimmune therapies [3]. - The company is focusing on filling gaps in its wild-type lung squamous carcinoma layout with PD-1/IL-15 and has ADC pipelines targeting HER3, B7H3, DLL3, among others [3]. Profit Forecast and Valuation - The company’s net profit is projected to be RMB 4.45 billion in 2025 and RMB 8.46 billion in 2026, with corresponding EPS of RMB 0.39 and RMB 0.73 [4][9]. - The target price is set at HKD 19.25, reflecting a 24x PE for 2026, with adjustments made based on the anticipated impact of product procurement [4][11].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.25 [1][4]. Core Insights - The company has announced a significant overseas deal for its long-acting peptide drug metabolism AI discovery platform, involving an upfront payment of USD 1.2 billion, potential R&D milestone payments of up to USD 3.5 billion, and sales milestone payments of up to USD 13.8 billion, along with a double-digit percentage royalty on net sales to AstraZeneca [1][2]. - This transaction is noted as the largest deal in the domestic pharmaceutical sector for the year, comparable to a previous major deal between 3SBio and Pfizer [1]. - The company is expected to benefit from the upfront payment, leading to a projected rapid year-on-year growth in net profit for 2026 [1]. - The long-acting metabolism platform is considered rare globally, with only Camurus having a similar platform, which enhances the company's competitive position in the overseas weight loss market [2]. Summary by Sections Transaction Details - The deal with AstraZeneca includes an upfront payment of USD 1.2 billion, potential R&D milestones of up to USD 3.5 billion, and sales milestones of up to USD 13.8 billion, along with a royalty on net sales [2]. - The platform includes core assets such as GIPR/GLP-1R and three preclinical weight loss pipelines, with plans for collaboration on four additional projects [2]. Platform Mechanism - The company possesses a leading liposome platform, and the fluid crystal technology allows for long-term release of active ingredients, enabling monthly or longer dosing [2]. Pipeline Potential - The company has a robust pipeline including EGFR ADC, which is expected to enter Phase III clinical trials both domestically and internationally, and other oncology and autoimmune therapies [3]. - The ADC pipeline targets HER3, B7H3, DLL3, and aims to address gaps in lung squamous carcinoma treatment [3]. Profit Forecast and Valuation - The projected net profits for the company from 2025 to 2027 are estimated at RMB 4.45 billion, RMB 8.46 billion, and RMB 5.60 billion respectively, with corresponding EPS of RMB 0.39, RMB 0.73, and RMB 0.49 [4][9]. - The company is assigned a PE ratio of 24 times for 2026, with a target price adjustment reflecting market conditions [4][11].

Group 1 - Dongcheng Pharmaceutical announced a share buyback plan, repurchasing approximately 4.03 million shares, which accounts for 0.49% of the total share capital [1] - The buyback was conducted through a centralized bidding method, with a total expenditure of approximately RMB 57.17 million [1] - The highest transaction price during the buyback was RMB 14.74 per share, while the lowest was RMB 13.87 per share [1] Group 2 - The news highlights a significant market reaction to external events, particularly related to Trump, which caused gold prices to drop sharply [1] - Over the previous two weeks, gold prices had surged by 21%, indicating high volatility in the market [1] - Various institutions have provided their outlooks on the future market trends following these events [1]

Investment Rating - The investment rating for the company is "Buy" for both A-shares and H-shares, maintained from previous assessments [7]. Core Insights - The company is expected to achieve significant revenue growth in 2025, with projected revenue of 3.25 billion RMB, representing an increase of 89% year-over-year. The net profit attributable to shareholders is forecasted to be 716 million RMB, marking a turnaround from previous losses [2][12]. - The company is advancing its overseas business development (BD) efforts, with expected contributions from key products and partnerships, including a notable deal with AbbVie for RC148, which includes a $650 million upfront payment [3][5]. - The domestic market is showing strong performance, with core products expected to maintain rapid revenue growth due to manageable price reductions in insurance renewals and potential approvals for new indications [2][4]. Revenue and Profit Forecast - Revenue projections for 2025 have been adjusted to 3.25 billion RMB, with a significant increase in net profit to 716 million RMB, reflecting a substantial recovery from previous losses [12][17]. - The company anticipates continued growth in 2026, with revenue expected to reach 7.83 billion RMB, driven by both domestic sales and international BD activities [11][12]. Pipeline Development - The clinical development of RC148 is progressing, with potential for global Phase III trials to start soon, which could enhance its market position significantly [3][4]. - The company is also advancing other key products, including the global Phase III clinical trials for its lead candidates, which are expected to contribute to future revenue growth [4][5]. Valuation and Price Target - The target price for A-shares is set at 151.81 RMB, while the target price for H-shares is 143.58 HKD, reflecting a premium of 18.80% based on recent valuations [5][14]. - The valuation adjustments are based on changes in the fair value of warrants and a decrease in debt financing needs, leading to an updated forecast for net profits in the coming years [12][14].

Core Viewpoint - China Resources Double Crane (华润双鹤) has received approval from the China Securities Regulatory Commission (CSRC) to publicly issue corporate bonds totaling up to 3 billion yuan, which will enhance its financial flexibility and support future growth initiatives [1][3]. Company Announcements - The company reported a stock price increase, closing at 18.76 yuan, up 0.21% from the previous week, with a market capitalization of 19.487 billion yuan, ranking 25th in the chemical pharmaceutical sector [1]. - The company’s subsidiary, Xi'an Jingxi Double Crane Pharmaceutical Co., Ltd., has obtained a drug registration certificate for Sodium Acetate Injection, which is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [2][3]. - The new product, Sodium Acetate Injection, is intended for extracellular fluid supplementation and correction of metabolic acidosis, which will enhance the company's product line and market competitiveness [2].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002898 证券简称：*ST赛隆 公告编号：2026-007 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别风险提示 1. 2026年1月30日，公司披露了《关于2025年度审计会计师事务所辞任的公告》（公告编号：2026- 006），因国府嘉盈会计师事务所（特殊普通合伙）（以下简称"国府嘉盈"）辞任公司2025年度财务报 表审计机构，为保证公司2025年度审计工作的正常开展，公司正积极与其他会计师事务所进行沟通，但 能否及时完成后任会计师事务所的聘任存在不确定性，公司将密切关注相关情况并根据进展及时履行信 息披露义务，敬请广大投资者充分注意投资风险。 2.本次业绩预告相关数据是公司财务部门初步测算的结果，由于国府嘉盈辞任公司2025年度财务报表审 计机构，因此本次业绩预告有关事项未经会计师事务所预审计，亦未与会计师事务所进行预沟通。由于 公司预计净利润为负值，若后续公司经审计的扣除后营业收入低于3亿元，或出现财务会计报告被出具 保留意见、无法表示意见或者否定意见的审计报告等其他不能消除退市风 ...